Immunoassay plate coating solution
- Reliable – quality-controlled coating buffer for reproducible results
- Versatile – compatible with chemiluminescent and colorimetric EIA/ELISA assays
- Convenient – save time using pre-made buffer. No more weighing, mixing or pH adjusting
HRP-conjugated secondary antibodies
for chemiluminescent immunodetection
- Performance – excellent signal in immunoblotting and ELISA applications
- Convenience – each antibody is demonstrated to provide optimal results with Advansta's protein detection systems
- Purity – each antibody is affinity purified to maximize specificity
Blocking solution for ELISAs and immunoassay plates
- Decreases background
- Decreases well-to-well variability
- Decreases non-specific binding
- Ready-to-use solution
Non-protein blocking solution for fluorescent and chemiluminescent Western blotting
- Low background - Protein-free block buffer for lower background with certain antibodies
- Optimized - Stabilizes fluorescence of WesternBright MCF fluorescent secondary antibodies
- Versatile - Compatible with fluorescent and chemiluminescent detection
Chemiluminescent substrate for ELISA applications
- Highest signal to noise ratio – for superior performance
- Broad linear dynamic range – for enhanced detection and precision
- Immediate light generation – for fast detection
- Cost effective – and reduced reagent consumption
Includes:
ELISABright Luminol reagent
ELISABright Peroxide reagent
In December of 2019, the SARS-CoV-2 virus, which causes the disease COVID-19, was first detected in Wuhan, China. The SARS-CoV-2 virus is a single-stranded RNA coronavirus that causes respiratory infections. The rapid spread of COVID-19 has resulted in a global pandemic which has caused an unprecedented social and economic disruption to daily life.
To aid in the advancement of infectious disease research, Advansta now offers recombinant forms of the Nucleocapsid and Spike Receptor Binding Domain (RBD) proteins encoded by the virus as well as ELISA kits to detect the IgG immune response to both the Nucleocapsid and Spike (RBD) proteins. Each protein is expressed in Escherichia coli or CHO K1 cells and affinity purified. The ELISA assays are designed for the qualitative measurement of human IgG, immunoglobulin that is produced in response to an antigen, against the Nucleocapsid or Spike (RBD) proteins from the SARS-CoV-2 virus. Each ELISA kit contains a high binding ELISA plate, a recombinant SARS-CoV-2 protein, Positive and Negative Control Serum, 1X EIA Coating Buffer, AdvanBlock-EIA, Anti-Human IgG HRP Conjugate, TMB Substrate and Stop Solution sufficient to perform one 96-well colorimetric ELISA assay.
Connect